Departments of Transplantation Medicine and.
Pediatric and Adolescent Medicine, Oslo University Hospital.
Ther Drug Monit. 2021 Jun 1;43(3):371-375. doi: 10.1097/FTD.0000000000000873.
Therapeutic drug monitoring of tacrolimus (Tac) is mandatory in solid organ transplant (SOT) recipients. Finger-prick microsampling is more flexible and tolerable during the therapeutic drug monitoring of tacrolimus and has been shown to be applicable in adult SOT recipients. In this study, a previously validated method applying volumetric absorptive microsampling (VAMS) to measure Tac in adults was cross-validated in a pediatric population.
Patients with SOT scheduled for standard posttransplant follow-up visits were recruited. Blood samples were obtained by trained phlebotomists using standard venipuncture and capillary microsampling, before the morning dose of Tac as well as 2 and 5 hours after dosing. Tac concentrations were quantified using liquid chromatography-tandem mass spectrometry. Concordance between Tac concentrations obtained with venipuncture and VAMS was evaluated using Passing-Bablok regression, calculation of absolute and relative differences, and percentage of samples within ±20% and ±30% difference.
A total of 39 SOT patients aged 4-18 years (22 male) were included. The median (range) predose venous blood concentration was 4.8 (2.6-13.6) mcg/L, with a difference between VAMS and venous blood samples of -0.2 ± 0.7 mcg/L. The relative mean difference was -1.3% [95% confidence interval (CI), -5.9% to 3.4%]. Ninety-two percent and 97% of the sample pairs demonstrated differences within ±20% and ±30%, respectively. Postdose (2 hours and/or 5 hours, n = 17) median concentration in venous blood was 7.9 (4.8-19.2) mcg/L. The difference between VAMS and venous blood samples was 0.1 ± 1.0 mcg/L, with a relative mean difference of -2.5% (95% confidence interval, -8.8% to 3.8%). Eighty-eight percent of the postdose sample pairs were within ±20% difference, and all were within ±30% difference.
Tac concentrations can be accurately measured using VAMS technology in pediatric SOT recipients. This makes home-based Tac monitoring feasible in the pediatric population.
在实体器官移植(SOT)受者中,他克莫司(Tac)的治疗药物监测是强制性的。与静脉采血相比,指末微采样在他克莫司治疗药物监测过程中更灵活、更耐受,并且已经在成人 SOT 受者中得到应用。在这项研究中,我们对之前经过验证的应用容量吸收微采样(VAMS)测量成人 Tac 的方法进行了交叉验证,以应用于儿科人群。
招募了计划进行标准移植后随访的 SOT 患者。在 Tac 早晨剂量前、给药后 2 小时和 5 小时,由经过培训的采血员使用标准静脉穿刺和毛细血管微采样采集血样。使用液相色谱-串联质谱法定量 Tac 浓度。采用 Passing-Bablok 回归、绝对和相对差异计算以及±20%和±30%差异内的样本百分比评估静脉采血和 VAMS 获得的 Tac 浓度之间的一致性。
共纳入 39 名 4-18 岁(22 名男性)SOT 患者。静脉血预剂量中位(范围)浓度为 4.8(2.6-13.6)μg/L,VAMS 与静脉血样本之间的差异为-0.2±0.7μg/L。相对平均差异为-1.3%[95%置信区间(CI),-5.9%至 3.4%]。92%和 97%的样本对之间的差异在±20%和±30%范围内。静脉血(n=17,2 小时和/或 5 小时)的中位浓度为 7.9(4.8-19.2)μg/L。VAMS 与静脉血样本之间的差异为 0.1±1.0μg/L,相对平均差异为-2.5%(95%CI,-8.8%至 3.8%)。88%的给药后样本对之间的差异在±20%以内,所有样本对之间的差异均在±30%以内。
VAMS 技术可准确测量儿科 SOT 受者的 Tac 浓度。这使得基于家庭的 Tac 监测在儿科人群中成为可能。